Cartesian Therapeutics Inc
Research Cartesian Therapeutics Inc (RNAC) on Bullrun: market cap USD 311.79M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRNAC
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 311.79M
- Financial periodQ2 2026
- RevenueUSD 0
- Net incomeUSD 15.77M
- Free cash flow-USD 21.35M
Valuation Snapshot
latest market cap is USD 311.79M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 400.00K | -USD 130.30M | -USD 79.40M | n/a | -5.02 | USD 125.14M | USD 12.68M | -USD 126.24M |
| FY2024 | USD 38.28M | -USD 77.42M | -USD 32.77M | n/a | -4.49 | USD 212.61M | USD 13.98M | -USD 6.80M |
| FY2023 | USD 26.00M | -USD 219.71M | -USD 51.37M | n/a | -49.76 | USD 76.91M | USD 10.96M | -USD 440.18M |
| FY2022 | USD 110.78M | USD 35.38M | -USD 32.83M | n/a | 0.1 | USD 106.44M | n/a | USD 93.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 311.79M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 187.54M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 461.49M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 111.57M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 172.92M | 3.4 | n/a | n/a |
| 2021 | 2021-12-31 | USD 403.01M | n/a | n/a | n/a |
About Cartesian Therapeutics Inc
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cartesian Therapeutics Inc's market cap?
Cartesian Therapeutics Inc's market capitalization is USD 311.79M.
What does Cartesian Therapeutics Inc do?
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.